SARS-CoV2 microarray
Introducing SARS-CoV-2 HuProt™: The Novel Coronavirus Microarray

All of our futures now depend on the human body’s ability to make antibodies to SARS-CoV-2, the virus that causes pandemic COVID-19 disease. And while it is now clear that recovered patients make protective antibodies against the disease – surprisingly it is the sickest patients making the most anti-SARS-CoV2 IgG antibodies [1].

The question is…why?

To help researchers answer this urgent question CDI Labs has created SARS-CoV-2 HuProt™: The Human Proteome Microarray with SARS-CoV-2 proteins. This new product combines >21,000 autologous human proteins with the S1 ACE2-receptor-binding spike & nucleocapsid from the virus that causes pandemic COVID-19 disease. With SARS-CoV-2 HuProt™, researchers can finally discover new antigen-specific immune responses that accompany different features of SARS-CoV-2 disease progression, clinical trial treatment response, and vaccine development.

Inquire here to purchase SARS-CoV-2 HuProt™ microarrays or serum profiling services:

Contact

Fields marked with an * are required
First Name
Last Name
Company or Institution
Email
Brief Project Description:

Why might human proteome microarrays with SARS-CoV-2 data be so important? There is evidence that cytokine release syndrome – similar to that seen in severe side effects of cancer immunotherapies – is involved in fatal COVID-19 cases [2]. CDI Labs collaborators at NYU have already demonstrated that similar side effects to cancer immunotherapies can be predicted by autoantibody signatures using HuProt™ arrays [3]. We made SARS-CoV-2 HuProt™ because we believe similar pre-existing autoantibody signatures may determine those most at risk for COVID-19 disease, may play a role in fatal cases, and can help guide clinical studies of COVID-19 treatments and vaccines. We think it’s time to Be Specific™ about COVID-19.

More about SARS-CoV-2 and pandemic COVID-19 disease:

Outbreak of the novel coronavirus (SARS-CoV-2) began in Wuhan China in late 2019 [4]. Novel coronavirus disease (COVID-19) is the symptomatic presentation of SARS-CoV-2 and presents with a diverse set of systemic and respiratory disorders including fever, cough, sore throat, fatigue, pneumonia with ground-glass opacities, acute cardiac injury, and respiratory distress [5]. Patients, particularly older men and people with underlying inflammatory conditions such as obesity, cardiovascular disease, COPD, and diabetes, are at higher risk of severe COVID-19 and death [6]. However, it is estimated that as many as 86% of SARS-CoV-2 infections are asymptomatic and do not result in COVID disease [7]. The particular reasons for this likely lie in the underlying immunologic response of the infected patients – but the reasons for this remain unclear. With SARS-CoV-2 HuProt™ Microarrays – these questions can now be answered.

More about SARS-CoV-2 HuProt™ Microarrays and Array Analysis Services:

SARS-CoV-2 HuProt™ Microarrays are available for direct purchase or an all-inclusive service. These arrays contain >21,000 full-length human proteins + the most important two SARS-CoV-2 proteins and is the most powerful tool ever created for mapping antigen-specific immunity. HuProt™ enables multi-isotype serum profiling of antibodies against three-dimensional antigens with a quantitative readout. It’s also useful for testing monoclonal antibodies, proteins, DNA, RNA, and even some small molecules.

The two SARS-CoV-2 proteins on these arrays are:

SARS-CoV-2 S1 Receptor-Binding Domain: This S1 ACE2 receptor binding spike is essential for entry of the novel coronavirus into human cells. Our S1 matches the sequence published here [8], is expressed in human cells, & has confirmed binding to ACE2.

SARS-CoV-2 Nucleocapsid: The nucleocapsid is the most abundant protein of a coronavirus. This version is purified from E.coli.

1. Jiang, H. et al. Global profiling of SARS-CoV-2 specific IgG/ IgM responses of convalescents using a proteome microarray. https://www.medrxiv.org/content/10.1101/2020.03.20.20039495v1.
2. SITC Statement on anti-IL-6/IL-6R for COVID-19.
3. Gowen, M. F. et al. Baseline antibody profiles predict toxicity in melanoma patients treated with immune checkpoint inhibitors. Journal of Translational Medicine 16, (2018).
4. Zhou, P. et al. Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin. https://www.biorxiv.org/content/10.1101/2020.01.22.914952v2.
5. Rothan, H. A. & Byrareddy, S. N. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. Journal of Autoimmunity 102433 (2020) doi:10.1016/j.jaut.2020.102433.
6. Banerjee, A. Estimating excess 1- year mortality from COVID-19 according to underlying conditions and age in England: a rapid analysis using NHS health records in 3.8 million adults. 23.
7. Li, R. et al. Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV2). Science eabb3221 (2020) doi:10.1126/science.abb3221.
8. Wan, Y., Shang, J., Graham, R., Baric, R. S. & Li, F. Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus. J Virol 94, e00127-20, /jvi/94/7/JVI.00127-20.atom (2020).